Observational evidence of third dredge-up occurrence in S-type stars with initial masses around 1 Msun

Context- S stars are late-type giants with spectra showing characteristic molecular bands of ZrO in addition to the TiO bands typical of M stars. Their overabundance pattern shows the signature of s-process nucleosynthesis. Intrinsic, technetium (Tc)-rich S stars are the first objects, on the Asymptotic Giant Branch (AGB), to undergo third dredge-up (TDU) events. Gaia exquisite parallaxes now allow to precisely locate these stars in the Hertzsprung-Russell (HR) diagram. Here we report on a population of low-mass, Tc-rich S stars, previously unaccounted for by stellar evolution models. Aims- Our aim is to derive parameters of a sample of low-mass Tc-rich S stars and then, by comparing their location in the HR diagram with stellar evolution tracks, to derive their masses and to compare their measured s-process abundance profiles with recently derived STAREVOL nucleosynthetic predictions for low-mass AGB stars. Methods- The stellar parameters were obtained using a combination of HERMES high-resolution spectra, accurate Gaia Data Release 2 (Gaia-DR2) parallaxes, stellar-evolution models and newly-designed MARCS model atmospheres for S-type stars. Results- We report on 6 Tc-rich S stars lying close to the 1 Msun (initial mass) tracks of AGB stars of the corresponding metallicity and above the predicted onset of TDU, as expected. This provides direct evidence for TDUs occurring in AGB stars with initial masses as low as ~ 1 Msun and at low luminosity, i.e. at the start of the thermally-pulsing AGB. We present AGB models producing TDU in those stars with [Fe/H] in the range -0.25 to -0.5. There is a reasonable agreement between the measured and predicted s-process abundance profiles. For 2 objects however (CD -29 5912 and BD +34 1698), the predicted C/O ratio and s-process enhancements do not match simultaneously the measured ones.Comment: Recommended for publication in A&A letter

Microcoil High-Resolution Magic Angle Spinning NMR Spectroscopy

Contains fulltext : 35644.pdf (publisher's version ) (Closed access

Plasma-Driven Synthesis of Self-Supported Nickel-Iron Nanostructures for Water Electrolysis

Nickel-based electrocatalysts are deemed as promising low-cost, earth-abundant materials in the development of the next-generation alkaline and anion exchange membrane water electrolyzers. Herein, a plasma-processing technique is presented for fabricating self-supported nanostructures from planar NiFe substrates and its performance for water splitting reactions. Irradiating the samples with helium plasma results in the formation of nano-tendrils, which are affixed to the metallic substrate. This unique design not only enhances charge and mass transport, but also increases the electrochemical surface area by 3 to 4 times, as compared to the unmodified/planar surfaces. For the benchmark 10 mAcm−2geo current density, the nanostructured electrodes demonstrate overpotentials of 330 and 354 mV for oxygen evolution reaction and hydrogen evolution reaction respectively in 1 M KOH. Moving forward, application of this technique can be extended for fabricating self-supported 3D substrates (e.g., foams, felts, perforated sheets), all of which find practical applications in energy conversion and storage devices

Titans metal-poor reference stars II. Red giants and CEMP stars

Representative samples of F-, G-, K-type stars located out of the Solar Neighbourhood has started to be available in spectroscopic surveys. The fraction of metal-poor ([Fe/H]~$\lesssim -0.8$~dex) giants becomes increasingly relevant to far distances. In metal-poor stars, effective temperatures ($T_{\mathrm{eff}}$) based on LTE spectroscopy and on former colour-$T_{\mathrm{eff}}$ relations of still wide use have been reported to be inaccurate. It is necessary to re-calibrate chemical abundances based on these $T_{\mathrm{eff}}$ scales in the multiple available surveys to bring them to the same standard scale for their simultaneous use. For that, a complete sample of standards is required, which so far, is restricted to a few stars with quasi-direct $T_{\mathrm{eff}}$ measurements. We aim at providing a legacy sample of metal-poor standards with proven accurate atmospheric parameters. We add 47 giants to the sample of metal-poor dwarfs of Giribaldi et al. 2021, thereby constituting the Titans metal-poor reference stars. $T_{\mathrm{eff}}$ was derived by 3D non-LTE H$\alpha$ modelling, whose accuracy was tested against interferometry and InfraRed Flux Method (IRFM). Surface gravity (log $g$) was derived by fitting Mg~I~b triplet lines, whose accuracy was tested against asteroseismology. Metallicity was derived using Fe II lines, which was verified to be identical to the [Fe/H] derived from non-LTE spectral synthesis. $T_{\mathrm{eff}}$ from 3D non-LTE H$\alpha$ is equivalent to interferometric and IRFM temperatures within a $\pm$46~K uncertainty. We achieved precision of $\sim$50~K for 34 stars with spectra with the highest S/N. For log $g$, we achieved a total uncertainty of $\pm$0.15~dex. For [Fe/H], we obtained a total uncertainty of $\pm$0.09~dex. We find that the ionization equilibrium of Fe lines under LTE is not valid in metal-poor giants.Comment: Accepted in A&

Recommendations for whole genome sequencing in diagnostics for rare diseases

In 2016, guidelines for diagnostic Next Generation Sequencing (NGS) have been published by EuroGentest in order to assist laboratories in the implementation and accreditation of NGS in a diagnostic setting. These guidelines mainly focused on Whole Exome Sequencing (WES) and targeted (gene panels) sequencing detecting small germline variants (Single Nucleotide Variants (SNVs) and insertions/deletions (indels)). Since then, Whole Genome Sequencing (WGS) has been increasingly introduced in the diagnosis of rare diseases as WGS allows the simultaneous detection of SNVs, Structural Variants (SVs) and other types of variants such as repeat expansions. The use of WGS in diagnostics warrants the re-evaluation and update of previously published guidelines. This work was jointly initiated by EuroGentest and the Horizon2020 project Solve-RD. Statements from the 2016 guidelines have been reviewed in the context of WGS and updated where necessary. The aim of these recommendations is primarily to list the points to consider for clinical (laboratory) geneticists, bioinformaticians, and (non-)geneticists, to provide technical advice, aid clinical decision-making and the reporting of the results

Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure:Design and rationale of the BioMEMS study

AimsHeart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF-related hospitalizations, further underscores the need for timely interventions. Proactive monitoring of intracardiac pressures, guided by pulmonary artery (PA) pressure, offers opportunities for efficient early-stage intervention, since haemodynamic congestion precedes clinical symptoms.MethodsThe BioMEMS study, a substudy of the MONITOR-HF trial, proposes a multifaceted approach integrating blood biobank data with traditional and novel HF parameters. Two additional blood samples from 340 active participants in the MONITOR-HF trial were collected at baseline, 3-, 6-, and 12-month visits and stored for the BioMEMS biobank. The main aims are to identify the relationship between temporal biomarker patterns and PA pressures derived from the CardioMEMS-HF system, and to identify the biomarker profile(s) associated with the risk of HF events and cardiovascular death.ConclusionSince the prognostic value of single baseline measurements of biomarkers like N-terminal pro-B-type natriuretic peptide is limited, with the BioMEMS study we advocate a dynamic, serial approach to better capture HF progression. We will substantiate this by relating repeated biomarker measurements to PA pressures. This design rationale presents a comprehensive review on cardiac biomarkers in HF, and aims to contribute valuable insights into personalized HF therapy and patient risk assessment, advancing our ability to address the evolving nature of HF effectively.Design and rationale of the BioMEMS study. QoL, quality of life. Graphical abstract is created with BioRender.com imag

Assignment of genetic linkage maps to diploid Solanum tuberosum pachytene chromosomes by BAC-FISH technology

A cytogenetic map has been developed for diploid potato (Solanum tuberosum), in which the arms of the 12 potato bivalents can be identified in pachytene complements using multicolor fluorescence in situ hybridization (FISH) with a set of 60 genetically anchored bacterial artificial chromosome (BAC) clones from the RHPOTKEY BAC library. This diagnostic set of selected BACs (five per chromosome) hybridizes to euchromatic regions and corresponds to well-defined loci in the ultradense genetic map, and with these probes a new detailed and reliable pachytene karyotype could be established. Chromosome size has been estimated both from microscopic length measurements and from 4′,6-diamidino-2-phenylindole fluorescence-based DNA content measurements. In both approaches, chromosome 1 is the largest (100–115 Mb) and chromosome 11 the smallest (49–53 Mb). Detailed measurements of mega-base-pair to micrometer ratios have been obtained for chromosome 5, with average values of 1.07 Mb/μm for euchromatin and 3.67 Mb/μm for heterochromatin. In addition, our FISH results helped to solve two discrepancies in the potato genetic map related to chromosomes 8 and 12. Finally, we discuss the significance of the potato cytogenetic map for extended FISH studies in potato and related Solanaceae, which will be especially beneficial for the potato genome-sequencing project

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701